Palo Alto, Calif.
Went public 3/24/2000 at $20 apiece
Filing Range:5.5 mil. shares @ $17 to $19
Shares Outstanding:20.19 mil. shares
Underwriters:Warburg Dillon Read
Chase H&Q/Prudential Vector Healthcare
(Data in $ millions)
Total Revenue -$.56
Net Loss -6.07 -6.35
Founded in 1998, InterMune Pharmaceuticals develops products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company has the exclusive license rights in the U.S. to ACTIMMUNE (interferon gamma-1b injection) for a range of indications, including chronic granulomatous disease, osteopetrosis, idiopathic pulmonary fibrosis, mycobacterial infections, systemic fungal infections and cystic fibrosis. InterMune currently markets ACTIMMUNE for chronic granulomatous disease, and has active development programs underway for the other indications, several of which are in mid- or advanced-stage human testing, also known as clinical trials. Idiopathic pulmonary fibrosis, mycobacterial infections and systemic fungal infections are serious and difficult to treat diseases that the company estimates represent a combined market opportunity for ACTIMMUNE of approximately $3.5 billion annually in the U.S.
Estimated proceeds of $75.7 will be used for clinical development and commercialization of existing products, new product licensing, working capital and general corporate purposes.
E.M. Warburg, Pincus & Co. LLC, Sanderling Ventures, BioAsia Investments LLC, Sofinnova Ventures, GenenTech Inc., Connetics Corp., Vernon International Ltd.
W. Scott Harkonen